
BACKGROUND Preeclampsia is a serious gestational hypertensive disorder that affects the constrictive mechanisms of the umbilical vessels. Due to limited pharmacotherapy for preeclampsia, natural products (e.g., terpenes) stand out as raw materials for new vasodilators. The objective of this study is to demonstrate the vasorelaxant effect of the sesquiterpenoid (E,E)-farnesol on human umbilical arteries (hUA-PE) and veins (hUV-PE) from preeclamptic pregnancies. STUDY DESIGN hUA-PE and hUV-PE rings were mounted in organ bath for isometric recordings (ex vivo). The binding mode of (E,E)-farnesol to vascular targets was determined by molecular docking (in silico). RESULTS (E,E)-farnesol (1 μmol/L-1.2 mmol/L) induced concentration-dependent vasodilation in the basal and stimulated tone of hUA-PE and hUV-PE. There was an arteriovenous difference in the potency to relax vessels pre-contracted with KCl (60 mmol/L) (EC50: hUA-PE = 295.50 ± 9.26 μmol/L vs. hUV-PE = 83.83 ± 12.22 μmol/L; p < 0.0001) or 5-HT (10 μmol/L) (EC50: hUA-PE = 451.00 ± 3.63 μmol/L vs. hUV-PE = 172.90 ± 7.43 μmol/L; p < 0.0001). Pre-incubation with (E,E)-farnesol (1.2 mmol/L;±30 min) reduced basal tone and prevented vasoconstriction (by KCl/5-HT) in a time-dependent manner. (E,E)-farnesol interacted with L-type VOCC (-5.1 kcal/mol) and 5-HT1B/1D/2A receptors (≤ - 6.0 kcal/mol). TEA (1 mmol/L; non-specific K+ channel blocker) modified the potency of (E,E)-farnesol to relax 5-HT-induced vasoconstriction in hUA-PE (EC50: 399.42 ± 6.44 μmol/L) and hUV-PE (EC50: 360.42 ± 9.54 μmol/L). CONCLUSIONS This is the first study to demonstrate the potent vasodilatory effect of (E,E)-farnesol in preeclamptic umbilical vessels. Our findings expand the evidence regarding the action of natural products on the fetoplacental vasculature and position (E,E)-farnesol as a promising terpene for restoring vascular homeostasis in preeclampsia.
Background: Pre-eclampsia (PE) continues to be a major risk to maternal and fetal health, complicating up to 5% of all pregnancies, with no proven pharmacological intervention to reduce its incidence at term. Screening for pre-eclampsia risk at 35-36 weeks' gestation has been associated with a 30% reduction in the incidence of the primary outcome of PE, in The PREVENT-PE Trial. Methods: We aimed to understand women's maternity and birth experiences in The PREVENT-PE Trial. Semistructured interviews were conducted with women (N = 80) from The PREVENT-PE Trial including those who were screened and had a timed birth (n = 37); those who were randomised to usual care (n = 31); and those who declined randomisation (n = 12). Data were subjected to a Template Analysis, based on findings from previous studies on maternity care experiences. Findings: We report on four key themes: Achieving Efficiencies with Research-embedded Clinical Care; Communicating Trial Information; Building Relationships with Care Providers; and Agency and Shared Decisionmaking. Maternity service delivery was deemed to be efficient as was the care they received during the trial. Volume of complex medical information caused concern; however, regular, consistent contact between women and their healthcare providers, helped women feel valued and understood; especially when they were provided with the opportunity to ask questions and have them answered. Conclusion: Participation in an intervention trial within maternity care should embed principles of effective communication, relational care, shared decision-making, and efficient service delivery. Addressing these with not only enhance maternal experience but may also further promote greater participation in research.